# Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

> **NCT05296525** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gamida Cell ltd** · enrollment: 13 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** GDA-201

## Key facts

- **NCT ID:** NCT05296525
- **Lead sponsor:** Gamida Cell ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-05
- **Primary completion:** 2024-04-22
- **Final completion:** 2024-04-22
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Study terminated by Sponsor.
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05296525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05296525, "Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05296525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*